Fecal Microbiota Transplantation & Alcoholic hepatitis

Alcohol, liver disease and the gut microbiota.


Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice.


Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.


Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.


Liver-Microbiome Axis in Health and Disease.


Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.


Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.


Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.


Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction.


Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.


Severe alcoholic hepatitis: current perspectives.


Alcohol or Gut Microbiota: Who Is the Guilty?


Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.


The gut microbiome.


Fecal microbiota transplantation in alcohol related liver diseases.


Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.


Microbiome as a therapeutic target in alcohol-related liver disease.


Microbiota-based treatments in alcoholic liver disease.


Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?


Microbiota, a key player in alcoholic liver disease.


Acute-on-chronic liver failure in patients with alcohol-related liver disease.


Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis.


Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.


Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.


Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease.


Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.


Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.


Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease.


Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.


Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.


Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.


Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review.


The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.


Intestinal microbiota in liver disease.


New paradigms in management of alcoholic hepatitis: a review.


[Medical Treatment of Alcoholic Liver Disease].


Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study.


Gut Microbiota as a Therapeutic Target for Metabolic Disorders.


Microbial Metabolites: Critical Regulators in NAFLD.


Are Probiotics Effective in Targeting Alcoholic Liver Diseases?


Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.


Current trials and novel therapeutic targets for alcoholic hepatitis.


Targeting Dysbiosis for the Treatment of Liver Disease.


[Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].


A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression.


Treatment of Gut Fermentation Syndrome With Fecal Microbiota Transplantation.


Predictors of steroid non-response and new approaches in severe alcoholic hepatitis.


Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.


Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis.


[Intestinal bacteria involved in nutritional liver disease killed by phagotherapy: a new therapeutic target].